The global antibody discovery market was valued at USD 8.8 billion in 2025. The market is projected to grow from USD 9.9 billion in 2026 to USD 23.2 billion by 2034, exhibiting a compound annual growth rate of 11.23% during the forecast period. Contrive Datum Insights presents this information in its report titled "Antibody Discovery Market Size, Share & Industry Analysis, By Technology (Phage Display, Hybridoma Technology, Transgenic Animal Platforms, Single B-Cell Technologies, Yeast Display, Mammalian and Cell-Free Display, AI and Computational Discovery), Antibody format (Full-Length Monoclonal Antibodies, Bispecific and Multispecific Antibodies, Antibody Fragments, Single-Domain Antibodies, Antibody-Drug Conjugate Antibodies, Polyclonal Antibodies), Offering (Discovery Services, Libraries and Reagents, Software and Informatics, Instruments and Platforms), Workflow stage (Target Identification and Validation, Hit Identification, Lead Optimization, Preclinical Characterization, Developability Assessment), Therapeutic area (Oncology, Autoimmune and Inflammatory Diseases, Infectious Diseases, Neurological Disorders, Metabolic and Cardiovascular Diseases, Other Therapeutic Areas), Antibody origin (Fully Human, Humanized, Chimeric, Murine), Target class (Immune Checkpoints, Cell-Surface Tumor Antigens, Cytokines and Cytokine Receptors, GPCRs and Ion Channels, Viral and Bacterial Antigens), End user (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Government and Public Research Bodies), Business model (Fee-for-Service, Platform Licensing, Collaborative Co-Development, In-House Discovery), and Regional Forecast, 2026-2034".
Antibody discovery covers the technologies, services, reagents, software and instruments used to find and optimise antibodies that bind a chosen disease target, from library screening and animal immunisation to computational design and developability testing. It takes the form of outsourced campaigns, licensed platforms, consumable libraries and in-house systems. Buyers are pharmaceutical and biotechnology developers, contract research organizations, and academic and public research groups.
AI and computational design adoption
AI and computational design adoption is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.23% a year, the technology lines exposed to it move fastest: AI and Computational Discovery compounds at 21.14%, taking its share of revenue from 12.05% to 26.97% and its value from USD 1.06 billion to USD 6.26 billion.
A more favourable outcome is possible. If computational design cuts discovery cycles faster than assumed, biotech funding recovers early, and bispecific and conjugate programmes start at a higher rate, 2034 revenue reaches USD 27.5 billion instead of the USD 23.2 billion the base case carries.
The downside is specific. Biotech funding stays tight, sponsors move more discovery in house, platform licensing terms tighten, and computational tools take longer to reach routine use, and 2034 revenue lands at USD 18.25 billion. Phage Display is the drag, 23.98% of the 2025 base compounding at 6.96% while the market runs at 11.23%.
Key Players Compete on Phage Display Volume and AI and Computational Discovery Growth
Competition in the global antibody discovery market runs along the technology axis, not the regional one. Phage Display holds 23.98% of 2025 revenue at USD 2.11 billion and remains the largest line through 2034 at 16.98%, making it the position hardest for a challenger to take. AI and Computational Discovery, growing at 21.14%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 8.8 billion.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Antibody format | Full-Length Monoclonal Antibodies | 52.05% · USD 4.58 billion | Bispecific and Multispecific Antibodies 18.8% |
| Offering | Discovery Services | 45.91% · USD 4.04 billion | Software and Informatics 19.07% |
| Workflow stage | Hit Identification | 30% · USD 2.64 billion | Developability Assessment 13.22% |
| Therapeutic area | Oncology | 43.98% · USD 3.87 billion | Neurological Disorders 14.24% |
| Antibody origin | Fully Human | 55% · USD 4.84 billion | — |
| Target class | Cell-Surface Tumor Antigens | 33.98% · USD 2.99 billion | GPCRs and Ion Channels 21.33% |
| End user | Pharmaceutical and Biotechnology Companies | 67.95% · USD 5.98 billion | Government and Public Research Bodies 16.56% |
| Business model | Fee-for-Service | 37.95% · USD 3.34 billion | Collaborative Co-Development 13.43% |
- Based on regional analysis, North America led the global antibody discovery market in 2025 with 43.5% of global revenue at USD 3.83 billion, reaching USD 9.05 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 23.5% in 2025 to 29.8% in 2034, with revenue growing from USD 2.07 billion to USD 6.91 billion.
- Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3% by 2034.
- Phage Display was the leading technology line in 2025, taking 23.98% of revenue at USD 2.11 billion.
- AI and Computational Discovery is projected to grow at 21.14% over the forecast period, the fastest of any technology line.
- The United States is the largest single country market at USD 3.45 billion in 2025, 39.2% of global revenue.
The report segments the market across nine axes; by technology, and by antibody format, offering, workflow stage, therapeutic area, antibody origin, target class, end user and business model; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 18.25 billion and USD 27.5 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.